HB0043

Small molecule

SShanghai Huaota Biopharmaceutical Co., Ltd.

HB0043 is one of 53 small molecule programs targeting Hidradenitis Suppurativa. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hidradenitis SuppurativaActive, not recruiting

Hidradenitis SuppurativaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

100 competitors in Hidradenitis Suppurativa

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Phase 3

7 2

Bimzelx

UCB

Phase 3

5 3

Jakafi

Incyte

Phase 3

4 4

Rhapsido

Novartis

Phase 3

3 5

Rinvoq

AbbVie

Phase 3

2 6

Taltz

Lutikizumab

3 8

Povorcitinib

Incyte

Phase 3

3 9

Tremfya

Johnson & Johnson

Phase 2

3 10

Skyrizi

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Not yet recruiting

Efficacy and Safety

NCT07449156

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa1 trial

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1/2·NCT06895499·15 enrolled

Efficacy and Safety1 trial

A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.

Not yet recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1/2·NCT07449156·21 enrolled

Adult1 trial

A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants

Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1·NCT06999083·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HB0043. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HB0043 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HB0043. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Huaota Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SShanghai Huaota Biopharmaceutical Co., Ltd.

HB0043

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hidradenitis Suppurativa1 trial

Efficacy and Safety1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News